Phase I Trial of N-acetylcysteine Shows Promise for Retinitis Pigmentosa
A phase I clinical trial indicates that N-acetylcysteine may slow cone degeneration in patients with retinitis pigmentosa.
Therapeutic Area
Therapeutic area intelligence for Retinitis Pigmentosa with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Kiora Pharmaceuticals is conducting Phase II study to evaluate KIO-301 in late-stage retinitis pigmentosa patients.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.